Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression
Abstract
:1. Background
2. Methods
2.1. Search Strategy
2.2. Eligibility Criteria
2.3. Data Extraction
2.4. Quality Evaluation
2.5. Statistical Analysis
3. Results
3.1. Literature Search
3.2. Characteristics of Eligible Studies
3.3. Overall Comparison
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Sanyal, A.; Charles, E.D.; Neuschwander-Tetri, B.A.; Loomba, R.; Harrison, S.A.; Abdelmalek, M.F.; Lawitz, E.J.; Halegoua-DeMarzio, D.; Kundu, S.; Noviello, S.; et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial. Lancet (Lond. Engl.) 2019, 392, 2705–2717. [Google Scholar] [CrossRef]
- Nascimbeni, F.; Romagnoli, D.; Ballestri, S.; Baldelli, E.; Lugari, S.; Sirotti, V.; Giampaoli, V.; Lonardo, A. Do nonalcoholic fatty liver disease and fetuin-a play different roles in symptomatic coronary artery disease and peripheral arterial disease? Diseases 2018, 6, 17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Pan, X.; Wen, S.W.; Bestman, P.L.; Kaminga, A.C.; Acheampong, K.; Liu, A. Fetuin-A in Metabolic syndrome: A systematic review and meta-analysis. PLoS ONE 2020, 15, e0229776. [Google Scholar] [CrossRef] [Green Version]
- Jensen, M.K.; Bartz, T.M.; Mukamal, K.J.; Djousse, L.; Kizer, J.R.; Tracy, R.P.; Zieman, S.J.; Rimm, E.B.; Siscovick, D.S.; Shlipak, M.; et al. Fetuin-A, type 2 diabetes, and risk of cardiovascular disease in older adults: The cardiovascular health study. Diabetes Care 2013, 36, 1222–1228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kahraman, A.; Sowa, J.P.; Schlattjan, M.; Sydor, S.; Pronadl, M.; Wree, A.; Beilfuss, A.; Kilicarslan, A.; Altinbas, A.; Bechmann, L.P.; et al. Fetuin-A mRNA expression is elevated in NASH compared with NAFL patients. Clin. Sci. (Lond. Engl. 1979) 2013, 125, 391–400. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.; Sun, M.; Jin, H.; Chen, H.; Ju, H. Fetuin-a to adiponectin ratio is a sensitive indicator for evaluating metabolic syndrome in the elderly. Lipids Health Dis. 2020, 19, 61. [Google Scholar] [CrossRef] [Green Version]
- Celebi, G.; Genc, H.; Gurel, H.; Sertoglu, E.; Kara, M.; Tapan, S.; Acikel, C.; Karslioglu, Y.; Ercin, C.N.; Dogru, T. The Relationship of circulating Fetuin-A with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J. Gastroenterol. 2015, 21, 139–145. [Google Scholar] [CrossRef]
- Denecke, B.; Graber, S.; Schafer, C.; Heiss, A.; Woltje, M.; Jahnen-Dechent, W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem. J. 2003, 376, 135–145. [Google Scholar] [CrossRef]
- Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ (Clin. Res. Ed.) 2009, 339, b2535. [Google Scholar] [CrossRef] [Green Version]
- Stang, A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2010, 25, 603–605. [Google Scholar] [CrossRef] [Green Version]
- Higgins, J.P.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. BMJ (Clin. Res. Ed.) 2003, 327, 557–560. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- DerSimonian, R.; Laird, N. Meta-analysis in clinical trials revisited. Contemp. Clin. Trials 2015, 45, 139–145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Egger, M.; Davey Smith, G.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin. Res. Ed.) 1997, 315, 629–634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ballestri, S.; Meschiari, E.; Baldelli, E.; Musumeci, F.E.; Romagnoli, D.; Trenti, T.; Zennaro, R.G.; Lonardo, A.; Loria, P. Relationship of serum fetuin-A levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. Metab. Syndr. Relat. Disord. 2013, 11, 289–295. [Google Scholar] [CrossRef] [PubMed]
- Cui, Z.; Xuan, R.; Yang, Y. Serum fetuin A level is associated with nonalcoholic fatty liver disease in Chinese population. Oncotarget 2017, 8, 107149–107156. [Google Scholar] [CrossRef] [Green Version]
- Dogru, T.; Genc, H.; Tapan, S.; Aslan, F.; Ercin, C.N.; Ors, F.; Kara, M.; Sertoglu, E.; Karslioglu, Y.; Bagci, S.; et al. Plasma fetuin-A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin. Endocrinol. 2013, 78, 712–717. [Google Scholar] [CrossRef]
- Ebert, T.; Linder, N.; Schaudin, A.; Busse, H.; Berger, J.; Lichtinghagen, R.; Keim, V.; Wiegand, J.; Karlas, T. Association of fetuin B with markers of liver fibrosis in nonalcoholic fatty liver disease. Endocrine 2017, 58, 246–252. [Google Scholar] [CrossRef]
- Şiraz, Ü.G.; Doğan, M.; Hatipoğlu, N.; Muhtaroğlu, S.; Kurtoğlu, S. Can fetuin-A be a marker for insulin resistance and poor glycemic control in children with type 1 diabetes mellitus? JCRPE J. Clin. Res. Pediatr. Endocrinol. 2017, 9, 293–299. [Google Scholar] [CrossRef]
- Haukeland, J.W.; Konopski, Z.; Aasheim, E.; Johansen, O.E.; Løberg, E.M.; Haaland, T.; Gladhaug, I.; Dahl, T.; Yndestad, A.; Aukrust, P.; et al. Elevated levels of fetuin a in nonalcoholic fatty liver disease. J. Hepatol. 2010, 52, S143–S144. [Google Scholar] [CrossRef]
- Haukeland, J.W.; Dahl, T.B.; Yndestad, A.; Gladhaug, I.P.; Løberg, E.M.; Haaland, T.; Konopski, Z.; Wium, C.; Aasheim, E.T.; Johansen, O.E.; et al. Fetuin A in nonalcoholic fatty liver disease: In vivo and in vitro studies. Eur. J. Endocrinol. 2012, 166, 503–510. [Google Scholar] [CrossRef]
- El-Ashmawy, H.M.; Ahmed, A.M. Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes. Eur. J. Gastroenterol. Hepatol. 2019, 31, 859–864. [Google Scholar] [CrossRef]
- Kurtoglu, S.; Dogan, M.; Hatipoglu, N.; Muhtaroglu, S.; Doganay, S.; Gul, U.; Elmali, F. Serum fetuin-a level for diagnosis hepatic steatosis in children with type 1 diabetes mellitus. Horm. Res. Paediatr. 2015, 84, 281–282. [Google Scholar]
- Lebensztejn, D.M.; Białokoz-Kalinowska, I.; Kłusek-Oksiuta, M.; Tarasów, E.; Wojtkowska, M.; Kaczmarski, M. Serum fetuin A concentration is elevated in children with non-alcoholic fatty liver disease. Adv. Med. Sci. 2014, 59, 81–84. [Google Scholar] [CrossRef]
- von Loeffelholz, C.; Horn, P.; Birkenfeld, A.L.; Claus, R.A.; Metzing, B.U.; Döcke, S.; Jahreis, G.; Heller, R.; Hoppe, S.; Stockmann, M.; et al. Fetuin A is a predictor of liver fat in preoperative patients with nonalcoholic fatty liver disease. J. Investig. Surg. 2016, 29, 266–274. [Google Scholar] [CrossRef]
- Li, Z.; Lin, M.; Liu, C.; Wang, D.; Shi, X.; Chen, Z.; Liu, Y.; Yang, S.; Li, X. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses. Cytokine 2018, 108, 145–150. [Google Scholar] [CrossRef]
- Lin, M.; Liu, C.; Liu, Y.; Wang, D.; Shi, X.; Chen, Z.; Liu, J.; Zheng, C.; Li, X.; Yang, S.; et al. Fetuin-B links nonalcoholic fatty liver disease to chronic kidney disease in obese Chinese adults: A cross-sectional study. Diabetes Metab. Res. Rev. 2018, 34, 50. [Google Scholar] [CrossRef]
- Mondal, S.A.; Dutta, D.; Kumar, M.; Singh, P.; Basu, M.; Selvan, C.; Mukhopadhyay, S. Neck circumference to height ratio is a reliable predictor of liver stiffness and nonalcoholic fatty liver disease in prediabetes. Indian J. Endocrinol. Metab. 2018, 22, 347–354. [Google Scholar]
- Nascimbeni, F.; Romagnoli, D.; Baldelli, E.; Sirotti, V.; Ballestri, S.; Bertolotti, M.; Lonardo, A. Nafld, Fetuin-A and Atherosclerosis Burden: Does Vascular Topography Matter? J. Hepatol. 2015, 62, S748–S749. [Google Scholar] [CrossRef]
- Ou, H.Y.; Yang, Y.C.; Wu, H.T.; Wu, J.S.; Lu, F.H.; Chang, C.J. Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J. Clin. Endocrinol. Metab. 2012, 97, 4717–4723. [Google Scholar] [CrossRef] [Green Version]
- Ou, H.Y.; Wu, H.T.; Hung, H.C.; Yang, Y.C.; Wu, J.S.; Chang, C.J. Endoplasmic reticulum stress induces the expression of fetuin-A to develop insulin resistance. Endocrinology 2012, 153, 2974–2984. [Google Scholar] [CrossRef] [Green Version]
- Pampanini, V.; Inzaghi, E.; Germani, D.; Alterio, A.; Puglianiello, A.; Alisi, A.; Nobili, V.; Cianfarani, S. Serum Fetuin-A levels in obese children with biopsy proven nonalcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2018, 28, 71–76. [Google Scholar] [CrossRef] [PubMed]
- Rametta, R.; Ruscica, M.; Dongiovanni, P.; Macchi, C.; Fracanzani, A.L.; Steffani, L.; Fargion, S.; Magni, P.; Valenti, L. Hepatic steatosis and PNPLA3 I148M variant are associated with serum Fetuin-A independently of insulin resistance. Eur. J. Clin. Investig. 2014, 44, 627–633. [Google Scholar] [CrossRef] [PubMed]
- Reinehr, T.; Roth, C.L. Fetuin-A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J. Clin. Endocrinol. Metab. 2008, 93, 4479–4485. [Google Scholar] [CrossRef] [Green Version]
- Roshdy, A.; Okash, H.; Soliman, A.; Maamoun, H.; Shaker, O.; Soliman, M.A.; Hamdy, A. Serum Fetuin A levels: Are They a reliable marker for hepatic steatosis and regional adiposity in renal transplant recipients? Transplant. Proc. 2015, 47, 2703–2706. [Google Scholar] [CrossRef]
- Sato, M.; Kamada, Y.; Takeda, Y.; Kida, S.; Ohara, Y.; Fujii, H.; Akita, M.; Mizutani, K.; Yoshida, Y.; Yamada, M.; et al. Fetuin-A negatively correlates with liver and vascular fibrosis in nonalcoholic fatty liver disease subjects. Liver Int. Off. J. Int. Assoc. Study Liver 2015, 35, 925–935. [Google Scholar] [CrossRef]
- Sonmez, A.; Nikolic, D.; Dogru, T.; Ercin, C.N.; Genc, H.; Cesur, M.; Tapan, S.; Karslioglu, Y.; Montalto, G.; Banach, M.; et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease. J. Clin. Lipidol. 2015, 9, 576–582. [Google Scholar] [CrossRef]
- Tanoglu, A.; Akyol, T.; Karagoz, E.; Yazgan, Y. The relationship between serum fetuin a and liver fibrosis in patients with non alcoholic fatty liver disease (NAFLD). Hepatol. Int. 2015, 9, S359. [Google Scholar]
- Wong, V.W.S.; Wong, G.L.H.; Chan, H.Y.; Yeung, D.K.W.; Chan, R.S.M.; Chim, A.M.L.; Chan, C.K.M.; Tse, Y.K.; Woo, J.; Chu, W.C.W.; et al. Bacterial endotoxin and non-alcoholic fatty liver disease in the general population: A prospective cohort study. Aliment. Pharmacol. Therap. 2015, 42, 731–740. [Google Scholar] [CrossRef]
- Yilmaz, Y.; Yonal, O.; Kurt, R.; Ari, F.; Oral, A.Y.; Celikel, C.A.; Korkmaz, S.; Ulukaya, E.; Ozdogan, O.; Imeryuz, N.; et al. Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: Relation with liver fibrosis. Ann. Clin. Biochem. 2010, 47, 549–553. [Google Scholar] [CrossRef] [Green Version]
- Zhu, J.; Wan, X.; Wang, Y.; Zhu, K.; Li, C.; Yu, C.; Li, Y. Serum fetuin B level increased in subjects of nonalcoholic fatty liver disease: A case-control study. Endocrine 2017, 56, 208–211. [Google Scholar] [CrossRef]
- Kim, M.; Lim, S.J.; Lee, H.-J.; Kim, S.Y.; Nho, C.W. Gomisin J Inhibits oleic acid-induced hepatic lipogenesis by activation of the AMPK-dependent pathway and inhibition of the hepatokine Fetuin-A in HepG2 cells. J. Agric. Food Chem. 2015, 63, 9729–9739. [Google Scholar] [CrossRef] [PubMed]
- Trepanowski, J.F.; Mey, J.; Varady, K.A. Fetuin-A: A novel link between obesity and related complications. Int. J. Obes. 2015, 39, 734–741. [Google Scholar] [CrossRef]
- Jung, T.W.; Youn, B.S.; Choi, H.Y.; Lee, S.Y.; Hong, H.C.; Yang, S.J.; Yoo, H.J.; Kim, B.H.; Baik, S.H.; Choi, K.M. Salsalate and adiponectin ameliorate hepatic steatosis by inhibition of the hepatokine fetuin-A. Biochem. Pharmacol. 2013, 86, 960–969. [Google Scholar] [CrossRef]
- Robinson, K.N.; Vazquez-Vidal, I.; Marques, C.; Andrade, F.C.D.; Aradillas-Garcia, C.; Teran-Garcia, M. Circulating triglycerides and the association of triglycerides with dietary intake are altered by alpha-2-heremans-schmid glycoprotein polymorphisms. J. Nutrigenet. Nutrigenom. 2017, 10, 75–83. [Google Scholar] [CrossRef]
- Kahraman, A.; Schlattjan, M.; Pronadl, M.; Wree, A.; Sydor, S.; Sowa, J.P.; Bechmann, L.; Syn, W.K.; Gerken, G.; Canbay, A. Reduction of fetuin-A in morbidly obese patients with NAFLD following weight loss by bariatric surgery. Hepatology 2012, 56, 882A. [Google Scholar]
- Alam, S.; Anam, K.; Islam, S.; Mustafa, G.; Mamun, A.A.; Ahmad, N. Clinical, anthropometric, biochemical and histological character of nonalcoholic fatty liver disease without Insulin Resistance. J. Clin. Exp. Hepatol. 2019, 9, 176–181. [Google Scholar] [CrossRef] [PubMed]
- Verras, C.G.; Christou, G.A.; Simos, Y.V.; Ayiomamitis, G.D.; Melidonis, A.J.; Kiortsis, D.N. Serum fetuin-A levels are associated with serum triglycerides before and 6 months after bariatric surgery. Hormones (Athens Greece) 2017, 16, 297–305. [Google Scholar] [PubMed]
- Marhaug, G.; Shah, V.; Shroff, R.; Varsani, H.; Wedderburn, L.R.; Pilkington, C.A.; Brogan, P.A. Age-dependent inhibition of ectopic calcification: A possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis. Rheumatology (Oxf. Engl.) 2008, 47, 1031–1037. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chattopadhyay, M.; Mukherjee, S.; Chatterjee, S.K.; Chattopadhyay, D.; Das, S.; Majumdar, S.S.; Mukhopadhyay, S.; Mukherjee, S.; Bhattarcharya, S. Impairment of energy sensors, SIRT1 and AMPK, in lipid induced inflamed adipocyte is regulated by Fetuin A. Cell. Signal. 2018, 42, 67–76. [Google Scholar] [CrossRef] [PubMed]
- Ampuero, J.; Ranchal, I.; Gallego-Duran, R.; Pareja, M.J.; Del Campo, J.A.; Pastor-Ramirez, H.; Rico, M.C.; Picon, R.; Pastor, L.; Garcia-Monzon, C.; et al. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. J. Gastroenterol. Hepatol. 2016, 31, 1611–1618. [Google Scholar] [CrossRef]
Study | Material | Country | NOS | Male Gender, n (%) | BMI | Mean Age | Study Type | Diagnosis of NAFLD | Overnight Fasting Blood | Methods | Frozen | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
(Ballestri et al., 2013) | [14] | Serum | Italy | 7 | 20(69.0) | 29.2 ± 5.0 | 64.5 ± 10.5 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Celebi et al., 2015) | [7] | Plasma | Turkey | 8 | 69(100.0) | 28.57 ± 3.40 | 31.8 ± 5.6 | Case-control | Liver biopsy specimens scored | Yes | ELISA | −80 °C |
(Cui et al., 2017) | [15] | Serum | China | 6 | 58(73.4) | 26.0 ± 3.0 | 42.8 ± 10.8 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Dogru et al., 2013) | [16] | Plasma | Turkey | 7 | 31(100.0) | 28.4 ± 2.97 | 31.0 ± 3.9 | Case-control | Liver biopsy specimens scored | Yes | ELISA | −80 °C |
(Ebert et al., 2017) | [17] | Serum | Germany | 6 | 52(51.4) | 28.7 ± 6.8 | 62.3 ± 16.4 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Şiraz Ü et al., 2017) | [18] | Serum | Turkey | 7 | 4(50.0) | 20.4 ± 5.6 | 14.0 ± 3.7 | Case-control | Ultrasonography | Yes | ELISA | −80 °C |
(Haukeland et al., 2010) | [19] | Plasma | Norway | 8 | 77(62.0) | 23.9 ± 3.0 | 62.7 ± 7.5 | Case-control | Liver biopsy specimens scored | No | ELISA | −80 °C |
(Haukeland et al., 2012) | [20] | Plasma | Norway | 8 | 67(60.0) | 30.5 ± 4.3 | 46.5 ± 11.6 | Case-control | Liver biopsy specimens scored | No | ELISA | −80 °C |
(El-Ashmawy and Ahmed, 2019) | [21] | Serum | Egypt | 8 | 55(52.4) | 27.8 ± 4.1 | 53.4 ± 9.2 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Kahraman et al., 2013) | [5] | Serum | Turkey | 6 | 55(23.1) | 37.6 ± 1.2 | 41.9 ± 0.9 | Case-control | Liver biopsy specimens scored | No | ELISA | 4 °C |
(Kurtoglu et al., 2015) | [22] | Serum | Turkey | 5 | 4(50.0) | 25.1 ± 3.0 | 15.3 ± 3.7 | Case-control | Ultrasonography | No | ELISA | NR |
(Lebensztejn et al., 2014) | [23] | Serum | Poland | 7 | 12(63.3) | 27.4 ± 7.3 | 13.0 ± 3.9 | Case-control | Ultrasonography | No | ELISA | NR |
(von Loeffelholz et al., 2016) | [24] | Plasma | Germany | 8 | 35(46) | 27.3 ± 1.1 | 61.0 ± 2.0 | Case-control | Liver biopsy specimens scored | Yes | ELISA | −80 °C |
(Li et al., 2018) | [25] | Serum | China | 7 | 283(36.2) | 28.2 ± 3.1 | 53.9 ± 7.0 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Lin et al., 2018) | [26] | Serum | China | 5 | 398(65.3) | 25.1 ± 3.0 | 61.9 ± 7.3 | Case-control | Ultrasonography | No | ELISA | NR |
(Mondal et al., 2018) | [27] | Serum | India | 8 | 26(56.5) | 27.5 ± 6.2 | 49.6 ± 12.2 | Case-control | Ultrasonography | Yes | ELISA | −80 °C |
(Nascimbeni et al., 2018) | [2] | Serum | Italy | 7 | 34(76) | 27.3 ± 19.1 | 69.0 ± 11.7 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Nascimbeni et al., 2015) | [28] | Serum | Italy | 7 | 62(78.2) | 27.0 ± 4.0 | 71.0 ± 10.0 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Ou et al., 2012a) | [29] | Serum | China | 7 | 51(56.7) | 26.1 ± 3.1 | 62.0 ± 10.0 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Ou et al., 2012b) | [30] | Serum | China | 7 | 25(55.6) | 25.8 ± 3.0 | 61.0 ± 10.0 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Pampanini et al., 2018) | [31] | Serum | Sweden | 6 | 5(55.6) | 31.0 ± 9.0 | 8.9 ± 2.3 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Rametta et al., 2014) | [32] | Plasma | Italy | 8 | 106(77.3) | 26.9 ± 3.4 | 49.7 ± 12.1 | Case-control | Liver biopsy specimens scored | Yes | ELISA | −80 °C |
(Reinehr and Roth, 2008) | [33] | Serum | USA | 8 | 9(75.0) | 27.6 ± 3.8 | 10.6 ± 2.8 | Case-control | Ultrasonography | Yes | ELISA | −80 °C |
(Roshdy et al., 2015) | [34] | Serum | Egypt | 5 | 24(77.4) | 41.26 ± 11.2 | 27.0 ± 2.7 | Case-control | Ultrasonography | No | ELISA | NR |
(Sato et al., 2015) | [35] | Serum | Japan | 6 | 151(86.3) | 26.5 ± 3.6 | 56.4 ± 6.9 | Case-control | Ultrasonography | Yes | ELISA | −80 °C |
(Sonmez et al., 2015) | [36] | Serum | Turkey | 8 | 17(70.0) | 27.72 ± 1.99 | 32.0 ± 6.0 | Case-control | Liver biopsy specimens scored | Yes | ELISA | −80 °C |
(Tanoglu et al., 2015) | [37] | Serum | Turkey | 5 | 35(83.3) | 29.72 ± 3.91 | 37.0 ± 6.0 | Case-control | Liver biopsy specimens scored | No | ELISA | NR |
(Wong et al., 2015) | [38] | Serum | China | 7 | 143(54.4) | 25.3 ± 3.4 | 51.0 ± 9.0 | Case-control | Ultrasonography | Yes | ELISA | NR |
(Yilmaz et al., 2010) | [39] | Serum | Turkey | 8 | 46(46.5) | 30.7 ± 4.9 | 47.0 + 9.0 | Case-control | Ultrasonography | Yes | ELISA | −80 °C |
(Zhu et al., 2017) | [40] | Serum | China | 7 | 54(58.7) | 25.8 ± 2.5 | 58.4 ± 10.9 | Case-control | Ultrasonography | No | ELISA | NR |
Study | AST (IU/mL) | ALT (IU/mL) | GGT (IU/mL) | TG (mmol/L) | LDL (mmol/L) | HDL (mmol/L) | HOMA-IR | |
---|---|---|---|---|---|---|---|---|
(Ballestri et al., 2013) | [14] | 22.00 | 27.00 | 23.00 | 1.86 | 1.16 | 0.40 | 1.50 |
(Celebi et al., 2015) | [7] | 52.00 | 116.00 | 60.00 | 2.00 | 1.21 | 0.41 | 3.50 |
(Cui et al., 2017) | [15] | 21.00 | 21.00 | 24.00 | 1.17 | 2.46 | 1.39 | 3.27 |
(Dogru et al., 2013) | [16] | 48.00 | 103.00 | 59.00 | 1.66 | 1.28 | 0.40 | 3.35 |
(Ebert et al., 2017) | [17] | 80.00 | 88.00 | 97.00 | 1.60 | 3.10 | 1.30 | NR |
(Şiraz Ü et al., 2017) | [18] | 17.00 | 17.00 | 11.00 | 1.05 | 0.87 | 0.61 | NR |
(Haukeland et al., 2010) | [19] | 83.00 | 81.00 | 55.00 | 1.73 | 0.39 | 0.11 | 2.11 |
(Haukeland et al., 2012) | [20] | 87.00 | 89.00 | 57.00 | 1.80 | 0.35 | 0.12 | 2.21 |
(El-Ashmawy and Ahmed, 2019) | [21] | 35.00 | 45.00 | 53.00 | 1.91 | 1.08 | 0.45 | 4.90 |
(Kahraman et al., 2013) | [5] | 28.00 | 35.00 | 39.00 | NR | NR | NR | NR |
(Kurtoglu et al., 2015) | [22] | 19.00 | 21.00 | 13.00 | NR | NR | NR | NR |
(Lebensztejn et al., 2014) | [23] | 55.00 | 57.00 | 30.00 | 1.80 | 1.08 | 0.42 | 3.67 |
(von Loeffelholz et al., 2016) | [24] | 45.00 | 80.00 | 90.00 | 1.25 | 1.19 | 0.45 | 3.30 |
(Li et al., 2018) | [25] | 83.00 | 79.00 | 51.00 | 2.17 | 3.69 | 1.31 | 4.09 |
(Lin et al., 2018) | [26] | 53.00 | 56.00 | 33.00 | NR | NR | NR | 3.23 |
(Mondal et al., 2018) | [27] | 61.00 | 60.00 | 26.00 | 1.80 | 3.20 | 1.00 | 1.10 |
(Nascimbeni et al., 2018) | [2] | 21.00 | 23.00 | 30.00 | 1.18 | 1.10 | 0.40 | 1.80 |
(Nascimbeni et al., 2015) | [28] | 27.00 | 25.00 | 36.00 | 1.21 | 1.13 | 0.55 | 1.91 |
(Ou et al., 2012a) | [29] | 28.00 | 31.00 | 36.00 | 1.51 | 1.30 | 0.48 | 1.13 |
(Ou et al., 2012b) | [30] | 31.00 | 29.00 | 33.00 | 1.44 | 1.33 | 0.53 | 2.90 |
(Pampanini et al., 2018) | [31] | 29.00 | 31.00 | 30.00 | NR | NR | NR | NR |
(Rametta et al., 2014) | [32] | 65.00 | 60.00 | 89.00 | 1.35 | 1.21 | 0.47 | 2.50 |
(Reinehr and Roth, 2008) | [33] | 28.00 | 28.00 | 47.00 | 1.12 | 2.98 | 1.35 | 3.90 |
(Roshdy et al., 2015) | [34] | 25.00 | 31.00 | 37.00 | NR | NR | NR | NR |
(Sato et al., 2015) | [35] | 46.00 | 33.00 | 66.00 | 1.56 | 1.31 | 0.54 | NR |
(Sonmez et al., 2015) | [36] | 61.00 | 126.00 | 67.00 | 1.91 | 2.93 | 1.04 | 3.92 |
(Tanoglu et al., 2015) | [37] | 37.00 | 35.00 | 88.00 | NR | NR | NR | NR |
(Wong et al., 2015) | [38] | 22.00 | 32.00 | 35.00 | 1.60 | 3.20 | 1.30 | 2.50 |
(Yilmaz et al., 2010) | [39] | 42.00 | 68.00 | 47.00 | 1.80 | 1.42 | 0.46 | 3.80 |
(Zhu et al., 2017) | [40] | 22.00 | 38.00 | 30.00 | 1.51 | 3.20 | 1.20 | NR |
Number of Studies | SMD (95% CI) | Z | p-Value | Heterogeneity | |||
---|---|---|---|---|---|---|---|
Q Statistic (DF; p-Value) | τ2 | I2 | |||||
Material | |||||||
Plasma | 7 | 1.0426 [0.6067; 1.4786] | 4.69 | 0.000 | 68.21 6 < 0.0001 | 0.30 | 91.20% |
Serum | 21 | 0.7546 [0.4626; 1.0466] | 5.07 | 0.000 | 224.35 20 < 0.0001 | 0.40 | 91.10% |
Study region | |||||||
Asia race | 15 | 0.6741 [0.3594; 0.9888] | 4.20 | 0.000 | 160.42 14 < 0.0001 | 0.33 | 91.30% |
Caucasian race | 13 | 1.0238 [0.6580; 1.3897] | 5.49 | 0.000 | 119.20 12 < 0.0001 | 0.38 | 89.90% |
Frozen | |||||||
Yes | 14 | 0.9508 [0.5704; 1.3312] | 4.9 | 0.000 | 163.53 13 < 0.0001 | 0.46 | 92.10% |
No | 14 | 0.5940 [0.3070; 0.8809] | 4.06 | 0.000 | 108.10 13 < 0.0001 | 0.24 | 88.00% |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pan, X.; Kaminga, A.C.; Chen, J.; Luo, M.; Luo, J. Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression. Int. J. Environ. Res. Public Health 2020, 17, 2735. https://doi.org/10.3390/ijerph17082735
Pan X, Kaminga AC, Chen J, Luo M, Luo J. Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression. International Journal of Environmental Research and Public Health. 2020; 17(8):2735. https://doi.org/10.3390/ijerph17082735
Chicago/Turabian StylePan, Xiongfeng, Atipatsa C. Kaminga, Jihua Chen, Miyang Luo, and Jiayou Luo. 2020. "Fetuin-A and Fetuin-B in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis and Meta-Regression" International Journal of Environmental Research and Public Health 17, no. 8: 2735. https://doi.org/10.3390/ijerph17082735